Recently Shabani et al., 2024 [56], investigated the influence of pharmacogenetics markers in the NAT2 and SLCO1B1 genes on tuberculosis treatment in the Iranian population; the NAT2 gene is responsible for isoniazid metabolism, and SLCO1B1 is responsible for rifampicin separately. The gene discussed is NAT2; the disease is tuberculosis.